Sure-Tech: Has Antidote Become the Core Asset, or Is This Still Mostly a SAFE Mark?
Antidote is no longer just a holding marked up through SAFE paper: it ended 2025 with about $37 million of unaudited revenue, about $46 million of free cash for operations, and about 36 thousand insured members for 2026. But at Sure-Tech level, the value layer still runs through milestone-based conversion terms, SAFE rounds, and a valuation that shows the holding value rather than the company's full implied value.
What This Follow-Up Is Isolating
The main article made the broader point: the real question at Sure-Tech is no longer just how much value sits in the portfolio, but how much of that value is actually accessible to public unitholders. This follow-up isolates Antidote because it is the one holding where the value layer rose together with an operating layer that now looks much more like a real business than a model.
So the question is not whether Antidote looks better than GeoX. That is already clear. The question is whether it now deserves to be read as Sure-Tech's core asset in the full economic sense, or whether the uplift is still sitting mainly in SAFE mechanics, milestones, and a private valuation layer.
The short answer: Antidote is no longer just a theoretical mark. There is now a business that looks larger, better funded, and more tangible than before. But that is still not the same thing as clean valuation proof. The operating layer has clearly strengthened, while Sure-Tech's value layer still runs through SAFE agreements, conversion mechanics, and an external valuation that shows the value of the holding, not the full company value.
What Is Already Proved At The Business Level
There is a good reason Antidote has moved to the center of the portfolio. This is no longer a company described only through vision. Antidote operates in the US individual health-insurance market, runs a telehealth platform, and says its revenue comes mainly from insured-member premiums in the ACA market in Ohio and Arizona, alongside Telehealth services to third parties. It also says it has no single-customer dependency.
The sharpest datapoint is the pace of expansion. Based on information Antidote gave the partnership, and which is unaudited, revenue rose from about $373 thousand in 2024 to about $37 million in 2025. That is almost a 100x jump in one year. The company also reported about $46 million of free cash for operations at year-end 2025, and said that based on its forecast and recent capital raises it does not expect to need additional investment over the 12 months after publication of the report in order to fund ongoing operations.
The insured-member count also changes the read. As of February 2026, Antidote said it had enrolled about 36 thousand insured members for the 2026 activity year, with revenue from those members to be recognized during 2026 according to the relevant coverage period. That does not yet prove profitability, but it does mean the move from “another portfolio company” to a business with a tangible customer base has already started.
This is exactly where precision matters. All of these operating datapoints were provided to the partnership by Antidote, were not prepared under standard accounting rules, and were not audited or reviewed. So readers now have more business proof than they had in prior years, but they still do not have a full set of audited financial statements on which to build without qualification.
| Layer | What Was Disclosed | What It Does Prove | What It Still Does Not Prove |
|---|---|---|---|
| Operations | About $37m of 2025 revenue versus about $373k in 2024 | Antidote no longer looks like a typical pre-revenue venture | There is still no audited set showing the quality of profitability |
| Cash | About $46m of free cash for operations at year-end 2025 | Immediate funding pressure appears lower | This is still unaudited company-provided information |
| 2026 demand base | About 36 thousand insured members as of February 2026 | A real operating base is entering the new year | The conversion into revenue and insurance economics still has to be shown |
| Private-market support | About $30.8m raised in 2025 through SAFE | The company can still attract capital beyond Sure-Tech | SAFE financing is not the same thing as one clean preferred-equity pricing event |
Where Antidote Has Already Become Sure-Tech's Core Asset
At the portfolio-weight level, the debate is close to over. At year-end 2025, Antidote carried a value of NIS 10.10 million and became the largest holding in the portfolio. That equals about 31.5% of Sure-Tech's private-investment portfolio. GeoX stood at only NIS 7.20 million at the same date, and Heka at NIS 5.37 million. If one holding now carries the center of gravity of the portfolio, it is Antidote.
But even here, the increase needs to be broken down rather than repeated as a headline. At year-end 2024, Antidote was carried at NIS 3.65 million. By year-end 2025 it stood at NIS 10.10 million. The total increase was NIS 6.45 million. Of that, NIS 4.01 million came from new follow-on investment by Sure-Tech during 2025, while only NIS 2.44 million was recognized as fair-value gain.
That distinction matters. Antidote's rise is not just a mark-up, but it also was not created purely by operating proof flowing automatically into value. Sure-Tech chose to put in more capital, concentrate more risk, and deepen exposure specifically in this name. Antidote therefore became a core asset not only because the appraiser assigned it a higher number, but because the partnership committed substantial follow-on capital to it during 2025.
That is exactly where the answer becomes more nuanced. If the question is whether Antidote is now Sure-Tech's core asset in terms of portfolio weight, management attention, and capital allocation, the answer is yes. If the question is whether that value already rests mainly on fully validated operating proof, the answer is more cautious.
Where The SAFE Layer Still Dominates The Story
To see why, you have to go back to the structure of the investment. Sure-Tech's first Antidote investment, in August 2023, was a $1 million SAFE. Under that agreement, automatic conversion is meant to happen only in a future preferred-equity financing in which the company raises at least $15 million, while amounts raised through SAFE or other convertible securities are explicitly excluded from that count. That is a small clause with real analytical importance.
Why does it matter? Because Antidote itself says it raised about $30.8 million in 2025 through SAFE. That is a lot of capital, and it clearly strengthens the case that this is still a company the private market is willing to fund. But that impressive funding does not necessarily equal the clean conversion event the 2023 SAFE was effectively waiting for. In other words, the funding layer got stronger, while the transparent price-discovery layer did not necessarily lock in.
The two investments Sure-Tech made in 2025 did not simplify the picture either. In October 2025 the partnership signed another SAFE for $500 thousand as part of a roughly $25 million financing round. Conversion there is set at the lower of a maximum company value tied to business milestones or the preferred-share price in a qualified financing with a 5% discount. On December 31, 2025, another SAFE was signed for $750 thousand, and that mechanism also relies on a milestone-based maximum company value, set above the October 2025 SAFE cap, or on the preferred-share price with a 5% discount.
That means Sure-Tech's Antidote position is currently built like a staircase of SAFE layers, not like a simple holding in common stock or even in one clearly priced preferred round. The model already reflects expected conversion, but the fact that conversion still depends on business milestones and future events makes clear that the value is not yet a clean market price.
The valuation report reinforces exactly that reading. It says Sure-Tech's year-end 2025 value in Antidote is based on the 12.2025 round and on a milestone achieved in January 2026 that set the conversion mechanism. It then breaks the holding across A10, A11, and A12 preferred shares, explicitly tying the October 2025 investment to A11 and the December 2025 investment to A12. In other words, even at the valuation stage, the holding is being read through modeled post-conversion preferred layers, not through an already observed equity price.
There is another detail that strengthens the caution. The appraiser says it does not present Antidote's company value itself for confidentiality reasons, only the value of Sure-Tech's holding. That is an important gap: readers get a holding value of $3.165 million, but not the full company valuation from which that number is derived. So even after the external valuation, a certain black-box layer remains between Antidote's business progress and the certainty of Sure-Tech's carrying value.
What Has To Happen For This To Move From Partial Proof To Cleaner Proof
The filing already gives three good tests for 2026. The first is the recognition test. The 36 thousand insured members disclosed in February 2026 need to turn into recognized revenue over the year in a way that keeps showing this is an expanding business, not just an initial enrollment spike.
The second is the funding test. Antidote's management estimates that no additional investment will be needed in the 12 months after publication of the report in order to fund ongoing operations. If that holds, it will strengthen the view that the company is now less dependent on frequent follow-on capital. If it does not hold, then even after the 2025 fundraising wave the cash layer will prove less durable than it currently appears.
The third is the pricing test. As long as the value layer still sits on SAFE, conversion assumptions, and a milestone that has been achieved but has not yet translated into one transparent equity round, Antidote will remain a core asset with more business certainty than pricing certainty. Only a clearer future capital event, or a performance path strong enough to sharply reduce dependence on the conversion assumptions, will begin to close that gap.
It is also worth remembering that operating proof in health insurance is not only about member growth. Antidote itself points to sensitivity to ACA changes, MLR, Risk Adjustment, premium approvals, and the continuation or expiration of APTC expansions after 2025. So 2026 is not only a commercial proof year. It is also a regulatory and industry proof year.
Bottom Line
If the question is framed correctly, the answer is actually sharp. Antidote has already become Sure-Tech's core asset, but not yet its fully proved asset.
It is already the core asset because it is the largest holding in the portfolio, because it is the clearest current combination of operating expansion and a wider cash layer, and because Sure-Tech itself chose to concentrate follow-on capital there. It is getting harder to dismiss it as just another detached accounting mark.
But this is still not full proof. The operating datapoints that strengthen the story are unaudited, the 2025 funding came mainly through SAFE, the 2025 conversion mechanics are milestone-based, and the valuation itself rests on a model that shows the holding value rather than the full company value. So anyone reading Antidote as “just another SAFE” is missing the real progress. Anyone reading it as already fully proved is moving too fast.
In other words, Antidote has already pushed Sure-Tech's story away from a portfolio that looks like paper value only. But until 2026 shows that operating expansion holds, that the cash layer really is sufficient, and that the SAFE layer starts converging toward cleaner pricing, part of the uplift will still sit in a mark-up layer rather than in fully validated proof.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.